Progress in ALS research requires a free flow of information between MDA-supported laboratory investigators and leaders in the drug-development industry
ALS, also known as amyotrophic lateral sclerosis and Lou Gehrig’s disease, is among the most feared diseases facing people in the U.S. and worldwide. In ALS, the motor neurons — the nerve cells of the brain and spinal cord that control muscle action — mysteriously deteriorate, often within just a few years, leaving behind orphaned muscle fibers. Without signals from motor neurons, voluntary...
Research and clinical trial updates
MDA welcomes two new muscle disease and ALS experts
As part of MDA’s bold plan to accelerate treatments and cures for neuromuscular diseases, two new scientific program officers have joined the MDA family: Amanda Haidet-Phillips, Ph.D., and Laura Hagerty, Ph.D. Under the leadership of MDA Senior Vice President and Scientific Program Director Grace Pavlath, Ph.D., they will...
Israel-based BioBlast Pharma says a California site will be added soon to locations already testing Cabaletta in oculopharyngeal muscular dystrophy in Israel and Canada
BioBlast Pharma, based in Tel Aviv, Israel, has been given clearance from the U.S. Food and Drug Administration (FDA) to test its experimental drug Cabaletta in the U.S. in people with oculopharyngeal muscular dystrophy (OPMD).
MDA-supported researcher Charles Gersbach and colleagues have developed a strategy to change dystrophin DNA that has shown promise in the lab
MDA research grantee Charles Gersbach, assistant professor of biomedical engineering at Duke University, and colleagues, recently announced an advance in gene modification that could turn out to be a game-changer for boys and young men with Duchenne muscular dystrophy (DMD). The team's results were published Feb.
This report on treatment development for Duchenne muscular dystrophy contains news about fighting fibrosis (scarring), treating DMD-related heart disease, exon skipping and the corticosteroid deflazacort
Development of treatments for Duchenne muscular dystrophy (DMD) continues to advance. Many of the new investigational drugs are potentially applicable to all DMD patients, while a few target those with specific mutations in the dystrophin gene.
Stanford University is collecting samples of blood, muscle and other tissues from people with neuromuscular disorders for use in research
Ever wondered how someone with a neuromuscular disorder in his or her family might contribute to research efforts in this field?
Meet Grace Pavlath, MDA's new scientific director
Grace Pavlath, an accomplished muscle disease researcher and a professor in the Department of Pharmacology at Emory University School of Medicine in Atlanta, recently joined MDA as senior vice president and scientific program director. She will be based in Atlanta initially and will eventually relocate to Washington, D.C.